Navigation Links
Semafore to Present at BIO CEO & Investor Conference
Date:2/8/2008

INDIANAPOLIS, Feb. 8 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that Edward L. Jacobs, president and chief executive officer, and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer, will present an update of the company's product development programs at 2:45 p.m. EST on Wednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New York City.

The update will include information about Semafore's lead product candidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1 clinical trials in solid tumors and multiple myeloma. The presentation will also include a review of the company's pipeline advancements and business development initiatives.

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's Web site at http://www.SemaforePharma.com.

Contacts:

Corporate Media

Semafore Pharmaceuticals Inc. Russo Partners LLC

Bob Marshall or Ed Jacobs David Schull or Timothy Engel

(480) 278-8200 (212) 845-4271


'/>"/>
SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Genomic Health to Present at BIO CEO & Investor Conference
3. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
4. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
5. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
6. Micromet to Present at Two Upcoming Investor Conferences
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Genelabs Technologies to Present at the BIO CEO & Investor Conference
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):